Is vitamin D deficiency a risk factor for osteonecrosis of the jaw in patients with cancer? A matched case-control study

J Craniomaxillofac Surg. 2019 Aug;47(8):1203-1208. doi: 10.1016/j.jcms.2019.03.007. Epub 2019 Mar 13.

Abstract

Purpose: A previous case-control histomorphometric study showed higher odds of osteomalacia in patients with bisphosphonate-related osteonecrosis of the jaw (BRONJ). Vitamin D deficiency causes osteomalacia and may therefore be involved in the pathogenesis of BRONJ. The present case-control study aimed at testing such hypothesis.

Materials and methods: BRONJ+ and BRONJ- patients treated with bisphosphonates were matched by sex (same) and age (within 5 years). Serum 25-hydroxy-vitamin D (25-OH-D), parathyroid hormone, bone alkaline phosphatase, total procollagen type 1 amino-terminal propeptide, carboxy-terminal collagen crosslinks, Dickkopf WNT signaling pathway inhibitor 1 and sclerostin were measured.

Results: The main outcome was vitamin D deficiency defined as 25-OH-D < 50 nmol/l. A total of 51 BRONJ+ and 73 BRONJ- patients were studied. The frequency (95% CI) of vitamin D deficiency was 59% (45%-72%) in BRONJ+ and 62% (48%-75%) in BRONJ- patients. This amounts to a difference of -3% (-22%-16%, p = 0.77) for BRONJ+ patients. Serum 25-hydroxy-vitamin D and parathyroid hormone were similar in BRONJ+ and BRONJ- patients. Among the bone metabolism markers, only sclerostin differed between the two groups, being higher in BRONJ+ patients.

Conclusion: The present matched case-control study suggests that vitamin D deficiency is not a risk factor for BRONJ.

Keywords: cancer; case-control study; osteonecrosis of the jaw; risk factor; vitamin D deficiency.

MeSH terms

  • Bisphosphonate-Associated Osteonecrosis of the Jaw*
  • Bone Density Conservation Agents / adverse effects*
  • Case-Control Studies
  • Diphosphonates
  • Humans
  • Neoplasms
  • Risk Factors
  • Vitamin D Deficiency* / drug therapy

Substances

  • Bone Density Conservation Agents
  • Diphosphonates